» Articles » PMID: 24294611

Side Population Cells As Prototype of Chemoresistant, Tumor-initiating Cells

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2013 Dec 3
PMID 24294611
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Classically, isolation of CSCs from tumors exploits the detection of cell surface markers associated with normal stem cells. Invariable expression of these cell surface markers in almost all proliferating tumor cells that albeit impart specific functionality, the universality, and clinical credibility of CSC phenotype based on markers is still dubious. Side Population (SP) cells, as defined by Hoechst dye exclusion in flow cytometry, have been identified in many solid tumors and cell lines and the SP phenotype can be considered as an enriched source of stem cells as well as an alternative source for the isolation of cancer stem cells especially when molecular markers for stem cells are unknown. SP cells may be responsible for the maintenance and propagation of tumors and the proportion of SP cells may be a predictor of patient outcome. Several of these markers used in cell sorting have emerged as prognostic markers of disease progression though it is seen that the development of new CSC-targeted strategies is often hindered by poor understanding of their regulatory networks and functions. This review intends to appraise the experimental progress towards enhanced isolation and drug screening based on property of acquired chemoresistance of cancer stem cells.

Citing Articles

Trophoblast Side-Population Markers are Dysregulated in Preeclampsia and Fetal Growth Restriction.

Wong G, Hartmann S, Simmons D, Ellis S, Nonn O, Cannon P Stem Cell Rev Rep. 2024; 20(7):1954-1970.

PMID: 39028417 PMC: 11445292. DOI: 10.1007/s12015-024-10764-w.


The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC.

Lee Y, Kim H, Kim H, Kang H, Lee D, Kim M J Mol Med (Berl). 2023; 101(11):1449-1464.

PMID: 37737908 PMC: 10663195. DOI: 10.1007/s00109-023-02369-6.


Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer.

Yamaguchi K, Yamamoto T, Chikuda J, Shirota T, Yamamoto Y Biomolecules. 2022; 12(2).

PMID: 35204785 PMC: 8961659. DOI: 10.3390/biom12020284.


Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.

Zhu N, Wang Q, Wu Z, Wang Y, Zeng M, Yuan Y J Virol. 2022; 96(5):e0194121.

PMID: 35019715 PMC: 8906414. DOI: 10.1128/jvi.01941-21.


MiR-199 Reverses the Resistance to Gemcitabine in Pancreatic Cancer by Suppressing Stemness through Regulating the Epithelial-Mesenchymal Transition.

Wei W, Wang L, Xu L, Liang J, Teng L ACS Omega. 2021; 6(47):31435-31446.

PMID: 34869970 PMC: 8637594. DOI: 10.1021/acsomega.1c02945.


References
1.
Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar S . Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 2006; 296(1-2):85-95. DOI: 10.1007/s11010-006-9302-8. View

2.
Misawa A, Katayama R, Koike S, Tomida A, Watanabe T, Fujita N . AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol Res. 2010; 19(1):23-33. DOI: 10.3727/096504010x12828372551759. View

3.
Fong D, Yeh A, Naftalovich R, Choi T, Chan M . Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett. 2010; 293(1):65-72. PMC: 2862867. DOI: 10.1016/j.canlet.2009.12.018. View

4.
Pihan G, Doxsey S . Mutations and aneuploidy: co-conspirators in cancer?. Cancer Cell. 2003; 4(2):89-94. DOI: 10.1016/s1535-6108(03)00195-8. View

5.
Zeller C, Dai W, Steele N, Siddiq A, Walley A, Wilhelm-Benartzi C . Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-76. DOI: 10.1038/onc.2011.611. View